Click here to download the pdf of the presentation.
We are committed to finding a cure for WM.
Nov 27th is Giving Tuesday
In 2012, NYC’s 92nd Street Y and the United Nations Foundation partnered to establish a day to celebrate giving. After all the Black Friday sales and Thanksgiving feasts, Giving Tuesday is a reminder of the greatness of giving after a… Continue reading
IWMF International Doctor – Patient Summit Sessions Online
The 5th International IWMF Doctor – Patient Summit was held in New York City from October 13-14.
The IWMF has generously provided videos of the sessions on their website.
To access the sessions, please CLICK HERE.
Notes from the WMFC Halifax Ed Forum
The first-ever Waldenstrom’s Macroglobulinemia Foundation of Canada’s (WMFC) educational forum in Halifax, Nova Scotia on October 27 provided four dozen patients, family members and hematology nurses the opportunity to learn from and speak with international and local WM experts, and… Continue reading
BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
Zanubrutinib was well tolerated and highly active in patients with Waldenström macroglobulinemia (WM), with more than 90% of patients experiencing a response, according to phase 1 data that were presented at the 10th International Workshop on Waldenström’s Macroglobulinemia… Continue reading
Ibrutinib Highly Active, Safe for Waldenström Macroglobulinemia
Source: https://www.oncnet.com/news/ibrutinib-highly-active-safe-waldenstrom-macroglobulinemia
Patients with symptomatic Waldenström macroglobulinemia (WM) benefit from first-line treatment with ibrutinib, which Steven P. Treon, MD, PhD, Bing Center for Waldenström Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, and colleagues describe as being highly active and safe… Continue reading
October is Membership Month!
| “When we work together we have the power to take problems head on and make a difference in our life and in the lives of others around us.” David DeNotaris As the fall… Continue reading |
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
A head-to-head, open-label, multicenter, phase 3 clinical trial comparing the efficacy and safety of zanubrutinib (BGB-3111) with ibrutinib in patients with Waldenström macroglobulinemia (WM) is underway (ClinicalTrials.org Identifier: NCT03053440).1 The study also seeks to evaluate the… Continue reading
FDA Approves First Chemotherapy-Free Treatment for Waldenström’s Macroglobulinemia
This morning, August 27, 2018, the US Food and Drug Administration (FDA) approved ibrutinib (IMBRUVICA, AbbVie) in combination with rituximab (RITUXAN) for the treatment of Waldenström’s macroglobulinemia. This combination is the first and only chemotherapy-free treatment option for patients with… Continue reading
Expert Highlights Potential of Zanubrutinib in Waldenstrom Macroglobulinemia
Zanubrutinib (BGB-3111), an investigational small molecule inhibitor of BTK, showed promising activity in patients with Waldenström macroglobulinemia (WM), according to updated results presented at the 2018 European Hematology Association Congress.
First author Judith Trotman, MBChB, FRACP, FRCPA, clinical professor of… Continue reading
